AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28376899
Drug: Oats consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oats consumption (70 g of oats twice a day for 4 weeks)
Trial: 15942151
Drug: Chlindamycine phosphate
RxNorm normalized name: Clindamycin Phosphate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlindamycine phosphate cream (placebo)
Trial: 12598351
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 60 mg/m2 alone
Trial: 12598351
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 60 mg/m2 and Cisplatin (CDDP) 50 mg/m2 every 4 weeks
Trial: 9890307
Drug: 0.025 to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 to 0.2 mg/h nitroglycerin patch
Trial: 2981827
Drug: Chlorpromazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (50 mg injections)
Trial: 2981827
Drug: Meperidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (50 mg injections)
Trial: 29902939
Drug: Twice-daily early
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily early therapeutic mobility (ETM)
Trial: 29902939
Drug: Once-daily early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily early therapeutic mobility (ETM)
Trial: 23759286
Drug: Enhanced cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive-behavioral therapy including a virtual reality protocol (ECT)
Trial: 23759286
Drug: Inpatient multimodal
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient multimodal treatment (IP)
Trial: 6381101
Drug: Hydrotubation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotubation with lactated Ringer's solution
Trial: 25037139
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg twice a day and cobimetinib 60 mg once a day 21/7
Trial: 25037139
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg twice a day and cobimetinib 80 mg once a day 14/14
Trial: 25037139
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg twice a day and cobimetinib 60 mg 28/0
Trial: 25037139
Drug: vemurafenib and
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib and cobimetinib (various dosing regimens)
Trial: 10214832
Drug: Dydrogesterone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (2.5 mg, 5 mg, 10 mg, 15 mg) combined with 2 mg of micronized 17beta-estradiol
Trial: 7605019
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at concentrations of 1, 3, 10, 30, and 100 ppm
Trial: 87965
Drug: T3 20
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 20 micrograms four times daily from surgery through the twelfth postoperative month
Trial: 87965
Drug: T3 20
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 20 micrograms four times daily
Trial: 30939507
Drug: TXA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (15 mg/kg IV before incision and a second identical dose 3 hours after the initial dose)
Trial: 28357822
Drug: Baxter elastomeric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baxter elastomeric LV10 InfusorTM pump using ceftazidime 6 g under 203 kPa
Trial: 28357822
Drug: Baxter elastomeric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baxter elastomeric LV10 InfusorTM pump using ucloxacillin 8 g
Trial: 21480103
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d., Bismuth subcitrate 240 mg b.i.d. for two weeks
Trial: 21480103
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d. (without Bismuth)
Trial: 17146320
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (18 mug)
Trial: 9167112
Drug: Extended-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release glipizide
Trial: 8467322
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose insulin infusion (5 mU/m2/min) during clamp A
Trial: 8467322
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose insulin infusion (60 mU/m2/min) during clamp B
Trial: 8467322
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug therapy (50 mg atenolol + 30 mg furosemide per day) prior to each clamp
Trial: 2431015
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% dermal cream
Trial: 20420270
Drug: Increased progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increased progesterone dosage
Trial: 20420270
Drug: Standard progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard progesterone dosage (Control)
Trial: 18488134
Drug: Web-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based administration of PFDI-20
Trial: 18488134
Drug: Web-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based administration of PFIQ-7
Trial: 15596631
Drug: Survey administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey administered to participants regarding attitudes, beliefs, and practices about ACP
Trial: 3300171
Drug: Citalopram (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (30-60 mg daily for at least 3 weeks)
Trial: 3300171
Drug: Amitriptyline (75-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75-225 mg daily for at least 3 weeks)
Trial: 30166290
Drug: 6-month self-rehabilitation
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month self-rehabilitation programme in addition to botulinum toxin injections (BTIs) and conventional physiotherapy
Trial: 30166290
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (BTIs) alone and conventional physiotherapy
Trial: 14695501
Drug: Tetracaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 4% gel (1.0 g)
Trial: 14695501
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (1.0 g of eucerin-plus cream)
Trial: 11056593
Drug: rhNGF, 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF, 0.1 microg/kg, subcutaneous injection 3 times per week for 48 weeks
Trial: 11056593
Drug: Placebo, subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, subcutaneous injection 3 times per week for 48 weeks
Trial: 8831327
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg/kg and Sch 1.5 mg/kg (Group I)
Trial: 8831327
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg and Sch 1.5 mg/kg (Group II)
Trial: 8831327
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg, alfentanil 40 micrograms/kg, and Sch 1.5 mg/kg (Group III)
Trial: 1336347
Drug: Piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (4 g) and tazobactam (500 mg) every 8 h
Trial: 1336347
Drug: Imipenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (500 mg) and cilastatin (500 mg) every 8 h
Trial: 31494097
Drug: AMG 714
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 714 (8 mg/kg, 7 intravenous doses over 10 weeks)
Trial: 27542322
Drug: Elbasvir/grazoprevir (EBR/GZR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir (EBR/GZR) 50mg/100mg once daily for 12 weeks (n=129)
Trial: 27542322
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) 400mg once daily plus pegylated interferon/ribavirin (PR) for 12 weeks (n=128)
Trial: 15142328
Drug: Repetitive short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive short VMs after Echovist‐300 injection
Trial: 15142328
Drug: Repetitive short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive short VMs after agitated saline injection
Trial: 11206674
Drug: Carvedilol 50
RxNorm normalized name: carvedilol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 50 mg once daily for 16 weeks
Trial: 11206674
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg once daily for 16 weeks
Trial: 9534010
Drug: Benfluorex (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfluorex (3 tablets daily)
Trial: 7831993
Drug: Lower neuroleptic
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower neuroleptic doses in the suicide group
Trial: 3049861
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied ophthalmic solution containing trimethoprim and polymyxin B (TP)
Trial: 3049861
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied ophthalmic solution containing trimethoprim, polymyxin B, and sulfacetamide
Trial: 29334997
Drug: Weekly self-monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Trial: 29334997
Drug: Monthly self-monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Trial: 25023711
Drug: CT-guided nucleoplasty
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided nucleoplasty with nerve root injection
Trial: 25023711
Drug: CT-guided transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided transforaminal lumbar epidural injections
Trial: 20883054
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide conjugate vaccine Prevenar 13 (PCV13)
Trial: 20883054
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of PCV13
Trial: 7673497
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (nontreated)
Trial: 6116607
Drug: Temazepam 20
RxNorm normalized name: temazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 20 mg plus whisky 100 ml
Trial: 27880064
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioural Therapy (Group-CBT) for 8 weeks
Trial: 25935314
Drug: Acceptance &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance & Commitment group Therapy (ACT-G), n=63
Trial: 21362011
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene protocol implemented in 7 nursing homes
Trial: 19761353
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral lamivudine 100 mg/day before and until at least 6 months after transplantation
Trial: 19761353
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and AHSCT without lamivudine (historical control group)
Trial: 19761353
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral lamivudine 100 mg/day
Trial: 18688944
Drug: Azithromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1000 mg) plus loperamide
Trial: 18688944
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg) plus loperamide
Trial: 24278400
Drug: Azithromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1000 mg)
Trial: 15318711
Drug: 4 fractions
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 fractions of 6.5 Gy each (overall dosage‐‐26 Gy) (2 fractions per week)
Trial: 15318711
Drug: 5 fractions
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 fractions of 6.5 Gy each (overall dosage‐‐32.5 Gy) (2 fractions per week)
Trial: 15318711
Drug: 4 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 daily fractions of 6.5 Gy each (overall dosage‐‐26 Gy)
Trial: 15318711
Drug: 23 fractions
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 fractions (overall dosage‐‐46 Gy) (5 weekly fractions)
Trial: 15318711
Drug: Standard low‐dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard low‐dosage fractionated irradiation
Trial: 9763719
Drug: Blister packaging
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blister packaging of antimalarial drugs
Trial: 9763719
Drug: Traditional means
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional means of dispensing antimalarial drugs (paper envelope)
Trial: 7512805
Drug: Antihistamine treatment
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine treatment with dimetindene (0.2 mg/kg) and ranitidine (1.25 mg/kg)
Trial: 26211735
Drug: 2% lavender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lavender essential oil via inhalation for 15 days
Trial: 26211735
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhalation of lavender essential oil)
Trial: 19671398
Drug: Healthy school
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy school meal (25-30% of daily caloric intake) for two months
Trial: 2577280
Drug: Timolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (10 mg b.i.d. for 5 days)
Trial: 2577280
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg b.i.d. for 5 days)
Trial: 30720034
Drug: Daily fresh
RxNorm normalized name: Vagisil Odor Block Daily Freshening Wipes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fresh pear consumption (2 medium-sized pears per day)
Trial: 26034956
Drug: Bundled intervention
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bundled intervention including mupirocin intranasally twice daily for up to 5 days, chlorhexidine-gluconate bathing for up to 5 days, and perioperative prophylaxis with vancomycin and cefazolin or cefuroxime for MRSA carriers; cefazolin or cefuroxime for others.
Trial: 12063773
Drug: Lovastatin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (up to 40 mg/day)
Trial: 9304634
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Trial: 9304634
Drug: 7 ml
RxNorm normalized name: ethanol 7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml of local anesthetic (2% lidocaine, 0.75% bupivacaine hydrochloride, and 1500 IU of hyaluronidase)
Trial: 8141715
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin with streptokinase (SK)
Trial: 8141715
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin with streptokinase (SK)
Trial: 2896506
Drug: Propranolol 2
RxNorm normalized name: propranolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 2 X 40 mg p.o.
Trial: 2896506
Drug: Betaxolol (Kerlone)
RxNorm normalized name: betaxolol hydrochloride Oral Tablet [Kerlone]
DrugBank: Betaxolol (DB00195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaxolol (Kerlone) 20 mg p.o.
Trial: 30320560
Drug: Pre-CAS group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-CAS group (300 mg of clopidogrel before stenting)
Trial: 30320560
Drug: Post-CAS group
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-CAS group (300 mg of clopidogrel after stenting)
Trial: 29928776
Drug: Weight-specified dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-specified dose of alcohol (0.7 g alcohol/kg body weight)
Trial: 22119513
Drug: E2 (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (0.05 or 0.1 mg)
Trial: 18844269
Drug: 0.6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 ml of a solution containing 30 units botulinum toxin
Trial: 18844269
Drug: 0.6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 ml saline (placebo)
Trial: 15031571
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nifedipine GITS
Trial: 11522047
Drug: Amiodarone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (200 mg four times daily as a loading dose)
Trial: 2737789
Drug: EpiDx (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiDx (720 mg/m2, 60 mg/m2 every 3 weeks)
Trial: 2737789
Drug: Doxorubicin (Dx)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (Dx) (540 mg/m2, 60 mg/m2 every 3 weeks)
Trial: 19083556
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg, twice daily in addition to 5‐mg hydrocodone tablets as needed
Trial: 19083556
Drug: 5‐mg hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg hydrocodone tablets as needed
Trial: 16868063
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg, orally, twice a day)
Trial: 16868063
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg, orally, twice a day)
Trial: 16868063
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and flutamide
Trial: 9832970
Drug: Triazolam (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125, 0.25, and 0.5 mg/70 kg)
Trial: 22791533
Drug: Weekly direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly direct observation with formal feedback (DO-FF)
Trial: 18194384
Drug: Single-dose lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose lenograstim (5 microg per kg once daily)
Trial: 18194384
Drug: Split-dose lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose lenograstim (2.5 microg per kg twice daily)
Trial: 15993933
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg/day) for 3 months prior to surgery
Trial: 12847809
Drug: Kan-Yang tablets
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kan-Yang tablets
Trial: 10228142
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via Turbuhaler (100 microgram per inhalation)
Trial: 10228142
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via pMDI (100 microgram per inhalation)
Trial: 8568123
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 2.4 mg/day, administered through a pressurized metered-dose inhaler for 4 weeks
Trial: 8568123
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied as no treatment or placebo during the study)